2 citations
,
August 2022 in “Emergency medicine international” This study found that a key gene signature, including FGF11, highlights the immunologic nature of keloid lesions, distinguishing them from normal fibroblasts and scars.
January 2025 in “International Journal of Genomics” This study identified three hub genes—BMP4, POSTN, and WNT5A—that are closely associated with keloid fibroblast hyperplasia, suggesting they may serve as potential biomarkers for inhibiting this condition. Further research is necessary to fully understand their roles in keloid development.
August 2026 in “The FASEB Journal” This study identified two key epigenetic-related genes, HR and SMYD4, which may act as potential biomarkers in keloid disease, suggesting new therapeutic avenues for further research.
January 2023 in “Research Square (Research Square)” This study identified m6A-related genes, particularly IGF2BP3, as significantly up-regulated in keloid patients, potentially implicating them in the condition's molecular mechanisms and suggesting targets for therapy.
6 citations
,
October 2024 in “International Journal of Dermatology” In this study, researchers conducted single-cell RNA sequencing to reveal that proinflammatory fibroblasts and vascular endothelial cells play significant roles in the immune microenvironment of keloids, suggesting potential targets for new therapeutic approaches.